STADA: Executive Board contract of Chairman of the Executive Board Hartmut Retzlaff extended by five years
09/08/2015 . Press Release
Bad Vilbel, September 8, 2015 – Today, on September 8, 2015, the Supervisory Board of STADA Arzneimittel AG extended the appointment of Hartmut Retzlaff as Chairman of the Executive Board by five years until August 31, 2021. Retzlaff has been Chairman of the Executive Board at STADA since 1993. His previous contract would have ended on August 31, 2016. Retzlaff is the Executive Board member responsible for the areas of Marketing and Sales, Corporate Strategy, Corporate Communications, Production, Purchasing and Procurement, Research and Development as well as Biotechnology.
Dr. Martin Abend, Chairman of the Supervisory Board at STADA Arzneimittel AG, had the following comment on the contract extension: "We are convinced that with Hartmut Retzlaff as Chairman of the Executive Board, STADA in the future will continue to be extremely well positioned to take advantage of the opportunities that present themselves and to be able to meet the major challenges the company faces. This is demonstrated by the successes he achieved in the past such as the growth-oriented course of internalization from a national company to a globally active group."
"In my nearly thirty years in the STADA Group, more than twenty of those as Chairman of the Executive Board, I have from time to time faced seminal decisions. To now continue developing STADA in the coming years and to lay the groundwork for upcoming challenges is particularly important for me, because I am very attached to the Group as a result of my long history with it", says Retzlaff with regard to his contract extension.
With the appointment, the Executive Board of STADA Arzneimittel AG continues to consist of Hartmut Retzlaff, Chairman of the Executive Board, Helmut Kraft, Chief Financial Officer, and Dr. Matthias Wiedenfels, Chief Business Development & Central Services Officer.
Hartmut Retzlaff, CEO of STADA Arzneimittel AG
Additional information for analysts:
STADA Arzneimittel AG / Investor Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /
Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / E-mail: firstname.lastname@example.org
Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /
Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail: email@example.com